Fluorescein-guided surgery for the resection of pilocytic astrocytomas: A multicentric retrospective study.
YELLOW 560 filter
central nervous system tumors
fluorescence-guided neurosurgery
neuro-oncology
pilocytic astrocytoma
sodium fluorescein
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
05
2022
accepted:
13
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Pilocytic astrocytomas (PAs) are relatively benign tumors, usually enhancing on post-contrast MRI and often characterized by a mural nodule within a cystic component. Surgical resection represents the mainstay of treatment, and extent of resection (EOR) is associated with improved survival. In this study, we analyzed the effect of sodium fluorescein (SF) on the visualization and resection of these circumscribed astrocytic gliomas. Surgical databases at two neurosurgical departments (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy and Department of Neurosurgery, University Medical Center Regensburg, Regensburg, Germany) were retrospectively reviewed to identify the cohort of patients with pilocytic astrocytoma who had undergone fluorescein-guided tumor resection at any of the centers between March 2016 and February 2022. SF was intravenously injected (5 mg/kg) immediately after the induction of general anesthesia. Tumors were removed using a microsurgical technique with the YELLOW 560 filter (Carl Zeiss Meditec, Oberkochen, Germany). Forty-four patients (25 males and 19 females; 26 pediatric patients, mean age of 9.77 years, range 2 to 17 years; and 18 adult patients, mean age of 34.39 years, range 18 to 58 years) underwent fluorescein-guided surgery. No side effects related to SF occurred. In all tumors, contrast enhancement on preoperative MRI was correlated with intense, heterogeneous yellow fluorescence with bright fluorescent cystic fluid. Fluorescein was considered helpful in distinguishing tumors from viable tissue in all cases except three patients due to faint fluorescein enhancement. Biopsy was intended in two operations, and partial resection was intended in three operations. Gross total resection was achieved in 24 cases out of 39 patients scheduled for tumor removal (61.54%), in five cases a minimal residual volume was highlighted by postoperative MRI despite the intraoperative subjective evaluation of complete tumor removal (12.82%); in the other 10 cases, the resection was subtotal with fluorescent residual spots to avoid neurological worsening (25.64%). The use of SF is a valuable method for safe fluorescence-guided tumor resection. Our data showed a positive effect of fluorescein-guided surgery on intraoperative visualization during resection of Pas, suggesting a possible role in improving the extent of resection of these lesions.
Identifiants
pubmed: 36016608
doi: 10.3389/fonc.2022.943085
pmc: PMC9395669
doi:
Types de publication
Journal Article
Langues
eng
Pagination
943085Informations de copyright
Copyright © 2022 Falco, Höhne, Broggi, Rubiu, Restelli, Vetrano, Schiariti, Mazzapicchi, Bonomo, Ferroli, Schebesch and Acerbi.
Déclaration de conflit d'intérêts
FA, JH, and K-MS received honoraria from the Carl Zeiss Meditec Company for lectures at International Congresses. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be constructed as a potential conflict of interest.
Références
Br J Neurosurg. 2019 Jun;33(3):343-347
pubmed: 30653383
Front Surg. 2019 Aug 13;6:49
pubmed: 31475153
World Neurosurg. 2020 Jan;133:e115-e120
pubmed: 31550545
J Neurosurg Sci. 2019 Dec;63(6):679-687
pubmed: 31037934
World Neurosurg. 2017 Dec;108:603-609
pubmed: 28935546
J Neurosurg. 2015 Jun;122(6):1360-9
pubmed: 25839919
Acta Neurochir (Wien). 2019 Jun;161(6):1099-1108
pubmed: 30989383
Cancer. 1984 May 1;53(9):2002-7
pubmed: 6704925
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Neuropathol Appl Neurobiol. 2013 Oct;39(6):693-705
pubmed: 23278243
Acta Neurochir (Wien). 2013 Aug;155(8):1431-5
pubmed: 23793962
J Neurosurg Pediatr. 2016 May;17(5):569-72
pubmed: 26722760
World Neurosurg. 2018 Feb;110:276-283
pubmed: 29180079
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Acta Neuropathol. 2005 Jan;109(1):93-108
pubmed: 15685439
J Clin Med. 2020 Jul 28;9(8):
pubmed: 32731376
Br J Neurosurg. 2021 Aug;35(4):451-455
pubmed: 33307861
J Neurosurg Sci. 2018 Dec;62(6):690-703
pubmed: 29790725
World Neurosurg. 2019 May;125:e158-e164
pubmed: 30682505
Cancer. 1987 Oct 1;60(7):1651-6
pubmed: 3621134
Cancers (Basel). 2019 Jul 29;11(8):
pubmed: 31362435
J Neurooncol. 2012 May;108(1):187-93
pubmed: 22367412
Acta Neuropathol. 2015 Jun;129(6):775-88
pubmed: 25792358
Acta Neurochir (Wien). 2013 Jul;155(7):1277-86
pubmed: 23661063
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
J Neurosurg. 2014 Nov;121(5):1115-23
pubmed: 25192475
Acta Neurochir (Wien). 2015 Sep;157(8):1377-8
pubmed: 26021579
J Neurooncol. 2009 Dec;95(3):377-382
pubmed: 19533024
Clin Cancer Res. 2018 Jan 1;24(1):52-61
pubmed: 29018053
Neuro Oncol. 2014 Jun;16(6):841-7
pubmed: 24470550
Acta Neurochir (Wien). 2015 Jun;157(6):899-904
pubmed: 25824557
Acta Neuropathol. 2009 Jun;117(6):657-65
pubmed: 19271226
J Neurosurg. 2019 Dec 6;:1-10
pubmed: 31812148
J Neurooncol. 2020 May;148(1):187-198
pubmed: 32342331
J Neurooncol. 2021 Jan;151(2):93-101
pubmed: 33131004
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Clin Neurol Neurosurg. 2015 Dec;139:125-8
pubmed: 26432995
Science. 1947 Aug 8;106(2745):130-1
pubmed: 17750790
J Child Neurol. 2013 May;28(5):625-32
pubmed: 23439714